Company / Free Cash Flow per Share
Protalix BioTherapeutics, Inc. Free Cash Flow per Share History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow per Share
-$0.03
FY2025
5-year range
-$0.59 / -$0.03
FY2021-FY2025
Trend
+90.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Free Cash Flow per Share has fluctuated over the past 10 years, ranging from $-0.74 in FY2019 to $-0.03 in FY2025.
Based on SEC 10-K filings.
-0.03 in FY2025.
Improved from $-0.22 to $-0.03 over the past 2 years.
Free Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, free cash flow per share increased 90.7% year-over-year.
- Lowest free cash flow per share in the period was in FY2019.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.03 | +90.7% |
| FY2024 | -$0.35 | -60.9% |
| FY2023 | -$0.22 | +62.8% |
| FY2022 | -$0.59 | -2.2% |
| FY2021 | -$0.57 | -1.2% |
| FY2020 | -$0.57 | +23.1% |
| FY2019 | -$0.74 | -270.7% |
| FY2017 | -$0.20 | +33.8% |
| FY2016 | -$0.30 | +13.3% |
| FY2015 | -$0.35 | -2169.7% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026